Expanding the European pharmaceutical and medical device business through the acquisition of Mono chem-pharm Produkte GmbH
First written in FY2025-H1. 1 of 2 entries say "Advanced", first in FY2026-H1. Latest entry: FY2026-H1.
3 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「(Europe) Sales to external customers increased substantially to ¥1.1538 billion, up 43.7% year on year. Dax Cosmetics in Poland contributed to the increase in revenue on the strong performance of "Perfecta" and "Hadalabo Tokyo," whose distribution countries were expanded. The Company has also been developing the eye-drop market since 2021, and "Rohto Dry-Aid" performed steadily. In addition, Mono contributed to sales.」
European sales increased 43.7% year on year, with specific contributions from Dax's brand expansion, development of the eye-drop market, "Rohto Dry-Aid" and sales by Mono chem-pharm Produkte GmbH. - FY2025-H1First statedAnnual report
「Europe accounts for 5.1% of the Company's regional sales, but further strengthening its over-the-counter pharmaceuticals and medical devices is essential to provide a broader range of product solutions in the European market, which has room for expansion. Mono chem-pharm Produkte GmbH has the capability to produce high-quality products compliant with the latest European pharmaceutical and medical device regulations, and further growth is expected.」
In light of the potential to expand Europe's 5.1% share of sales, the Company described for the first time its acquisition of Mono chem-pharm Produkte GmbH, a manufacturer and distributor of pharmaceuticals and medical devices, to expand its product solutions in the European market. The company became a consolidated subsidiary in August 2024 with a 51.0% voting rights interest; the purchase price was ¥4.88 billion and goodwill was ¥1.715 billion.